D.A. Davidson & CO. increased its holdings in shares of Celgene Co. (NASDAQ:CELG) by 1.6% in the second quarter, according to its most recent disclosure with the SEC. The firm owned 54,009 shares of the biopharmaceutical company’s stock after purchasing an additional 868 shares during the period. D.A. Davidson & CO.’s holdings in Celgene were worth $4,289,000 as of its most recent filing with the SEC.

A number of other institutional investors have also bought and sold shares of CELG. Two Sigma Advisers LP grew its holdings in Celgene by 361.3% during the fourth quarter. Two Sigma Advisers LP now owns 3,134,127 shares of the biopharmaceutical company’s stock worth $327,077,000 after purchasing an additional 2,454,703 shares during the period. Old Mutual Global Investors UK Ltd. grew its holdings in Celgene by 4,047.3% during the first quarter. Old Mutual Global Investors UK Ltd. now owns 1,576,831 shares of the biopharmaceutical company’s stock worth $140,669,000 after purchasing an additional 1,538,810 shares during the period. Natixis boosted its holdings in shares of Celgene by 245.6% during the first quarter. Natixis now owns 1,746,416 shares of the biopharmaceutical company’s stock worth $155,798,000 after acquiring an additional 1,241,120 shares during the period. HealthCor Management L.P. boosted its holdings in shares of Celgene by 217.6% during the fourth quarter. HealthCor Management L.P. now owns 1,725,000 shares of the biopharmaceutical company’s stock worth $180,021,000 after acquiring an additional 1,181,820 shares during the period. Finally, Clearbridge Investments LLC boosted its holdings in shares of Celgene by 17.0% during the fourth quarter. Clearbridge Investments LLC now owns 6,316,829 shares of the biopharmaceutical company’s stock worth $659,224,000 after acquiring an additional 916,173 shares during the period. Institutional investors and hedge funds own 77.71% of the company’s stock.

In related news, Director Gilla Kaplan sold 27,750 shares of the business’s stock in a transaction that occurred on Friday, May 18th. The stock was sold at an average price of $78.66, for a total value of $2,182,815.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director James J. Loughlin sold 17,750 shares of the business’s stock in a transaction that occurred on Monday, June 4th. The shares were sold at an average price of $78.96, for a total value of $1,401,540.00. The disclosure for this sale can be found here. Over the last quarter, insiders sold 58,500 shares of company stock valued at $4,608,365. 0.39% of the stock is currently owned by corporate insiders.

A number of brokerages have recently issued reports on CELG. Zacks Investment Research upgraded Celgene from a “sell” rating to a “strong-buy” rating and set a $102.00 price objective for the company in a report on Wednesday, August 1st. Mizuho restated a “buy” rating and set a $129.00 price objective on shares of Celgene in a report on Tuesday, July 31st. SunTrust Banks restated a “hold” rating and set a $101.00 price objective on shares of Celgene in a report on Friday, July 27th. Morgan Stanley boosted their price objective on Celgene from $91.00 to $93.00 and gave the stock an “equal weight” rating in a report on Friday, July 27th. Finally, Cowen restated a “buy” rating and set a $150.00 price objective on shares of Celgene in a report on Tuesday, July 10th. Two research analysts have rated the stock with a sell rating, thirteen have issued a hold rating, twenty have given a buy rating and two have issued a strong buy rating to the company’s stock. The company has a consensus rating of “Buy” and an average target price of $121.85.

Shares of CELG stock opened at $91.92 on Friday. The company has a debt-to-equity ratio of 5.76, a current ratio of 1.52 and a quick ratio of 1.40. The company has a market capitalization of $63.52 billion, a P/E ratio of 12.68, a P/E/G ratio of 0.56 and a beta of 1.32. Celgene Co. has a 1 year low of $74.13 and a 1 year high of $147.17.

Celgene (NASDAQ:CELG) last issued its quarterly earnings results on Thursday, July 26th. The biopharmaceutical company reported $2.16 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.11 by $0.05. The business had revenue of $3.81 billion during the quarter, compared to analysts’ expectations of $3.70 billion. Celgene had a return on equity of 87.28% and a net margin of 19.81%. The firm’s revenue for the quarter was up 16.6% compared to the same quarter last year. During the same period in the previous year, the company posted $1.82 earnings per share. analysts predict that Celgene Co. will post 7.64 earnings per share for the current year.

Celgene declared that its Board of Directors has approved a stock repurchase plan on Thursday, May 24th that permits the company to buyback $3.00 billion in shares. This buyback authorization permits the biopharmaceutical company to repurchase up to 5.4% of its stock through open market purchases. Stock buyback plans are usually an indication that the company’s board of directors believes its shares are undervalued.

About Celgene

Celgene Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapies for the treatment of cancer and inflammatory diseases worldwide. It offers REVLIMID, an oral immunomodulatory drug for multiple myeloma (MM), myelodysplastic syndromes (MDS), and mantle cell lymphoma; POMALYST/IMNOVID to treat multiple myeloma; OTEZLA, a small-molecule inhibitor of phosphodiesterase 4 for psoriatic arthritis and psoriasis; and ABRAXANE, a solvent-free chemotherapy product to treat breast, non-small cell lung, pancreatic, and gastric cancers.

See Also: What is a closed-end mutual fund (CEF)?

Want to see what other hedge funds are holding CELG? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Celgene Co. (NASDAQ:CELG).

Institutional Ownership by Quarter for Celgene (NASDAQ:CELG)

Receive News & Ratings for Celgene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene and related companies with MarketBeat.com's FREE daily email newsletter.